Navigation Links
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Date:9/3/2007

0.001).

The study also showed both treatment arms to yield similarly low rates of mortality and myocardial infarction. The mortality rates were 8.6 percent for the CYPHER(R) Stent and 7.9 percent for the bare metal stent (p=0.850), the Q- wave myocardial infarction rate for each treatment arm was 1.1 percent (p=1.00) and the non-Q-wave myocardial infarction rates were 7.4 percent for the CYPHER(R) Stent and 5.1 percent for the bare metal stent (p=0.388).

Also importantly, the study did not find a significant difference in the rates of stent thrombosis between the CYPHER(R) Stent and the bare metal stent, regardless of whether protocol or Academic Research Consortium (ARC) definitions were employed. When the protocol definitions were used, the rates of acute and subacute stent thrombosis were 0.0 percent for the bare metal stent and 1.1 percent for the CYPHER(R) Stent (p=0.25). The late stent thrombosis rates were 0.0 percent for the bare metal stent and 1.7 percent for the CYPHER(R) Stent (p=0.12). The definite/probable ARC definition identified a stent thrombosis rate of 4.2 percent for the CYPHER(R) Stent versus 1.7 percent for the bare metal stent (p=0.199). The definite/probable/possible ARC definition yielded a stent thrombosis rate of 6.5 percent for the CYPHER(R) Stent versus 3.5 percent for the bare metal stent (p=0.216). While there were numeric differences in the timing of such events between the CYPHER(R) Stent and the bare metal stent, at no point throughout the five-year period were the differences statistically significant.

"The results presented today reaffirm the long-term clinical benefits of the CYPHER(R) Stent compared to bare metal stents," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "As previously announced, Cordis is expanding the E-SIRIUS Trial to eight years of follow-up to provide physicians with longer term data about the CYPHER(R) Stent that will assist them in making inf
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
3. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
4. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
5. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and HOUSTON, TX , Feb. ... "Company") (TSX-V: EPI) and Bloom Burton & Co. Ltd. ... voluntary contractual lock-up (the "Lock-Up") 2,353,130 common shares of ... Shares originally subject to the Lock-Up. Of the Common ... free trading immediately upon release from the Lock-Up while ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated ... its,randomized, blinded, placebo-controlled phase 2 clinical trials ... rheumatoid,arthritis (RA) will be featured at the ... Rheumatology meeting, June,13-16, 2007 in Barcelona, Spain., ...
... study results confused the public about the,need and ... /PRNewswire/ -- The onslaught of,anti-stent news reports over ... that angioplasty doesn't work and its use should,decrease. ... their cardiologists about the benefits of stenting. , ...
Cached Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3To Stent or Not: Is That the Question? 2
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... International Symposium on Malignant Mesothelioma on Monday, March 2. ... Regency Bethesda in Bethesda, Maryland. The following award recipients ... to the mission to cure mesothelioma. , The Klaus ... to Miriam Ratner. Miriam runs the Meso Foundation’s monthly ...
(Date:2/28/2015)... Orlando, FL (PRWEB) February 28, 2015 ... community organization has sponsored visitor health insurance programs for ... 25 years. Most Indian elderly parents traveling to the ... conditions such as diabetes and blood pressure. These diseases ... do not even list them as medical conditions. There ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... urinate, affects the quality of life of many women. ... can tolerate oral medications and may benefit from other therapies. ... is conducting a study to compare the effect of two ... trying other treatments. Patients are currently being enrolled in ...
... February 29, 2012 A new method for creating ... Institute of New York University (NYU-Poly), promises to greatly ... heart disorders and Alzheimer,s disease, as well as aid ... , In addition, applied differently, this same development could ...
... new way of measuring the potential success rate of an ... in vitro fertilisation (IVF). According to the findings published ... fluid within a woman,s ovaries that surrounds the egg or ... embryo is more likely to lead to pregnancy. "We ...
... TUESDAY, Feb. 28 (HealthDay News) -- Taking the hallucinogen ecstasy ... lead to poorer motor control in infants, a new study ... history before and during pregnancy. The women were taking part ... which looks at recreational drug use among pregnant women. Most ...
... elderly cancer patients are evolving as more of the population ... To address these issues and others, national thought leaders ... the Kimmel Cancer Center at Jefferson (KCC) in ... an overview of the latest advances in the understanding and ...
... all deaths in the United States are linked to behavioral ... Despite these causal links, of the $2 trillion spent annually ... that is devoted to addressing behavioral and social risk factors. ... behavioral and social sciences with a new $500,000 grant from ...
Cached Medicine News:Health News:Women & Infants studying therapies to relieve urinary urge incontinence 2Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:New test can better predict successful IVF embryos, scientists say 2Health News:Ecstasy Use During Pregnancy May Harm Fetus: Study 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: